Contineum Therapeutics, Inc.

NASDAQ•CTNM

CEO: Mr. Carmine N. Stengone MBA, MS

セクター: Healthcare

業種: Biotechnology

上場日:

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

連絡先情報

10578 Science Center Drive, Suite 200, San Diego, CA, 92121, United States

858-333-5280

www.contineum-tx.com

時価総額

$506.30M

PER (TTM)

-7.1

17.5

配当利回り

52週高値

$16.33

52週安値

$3.35

52週レンジ

81%

順位59Top 87.6%

2.2

F-Score

改良版 Piotroski 分析

4年ファンダメンタル

弱い • 2.2 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2022-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.49+0.00%

直近4四半期の推移

フリーCF

-$13.08M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Strong Cash Position Maintained Cash reserves reached $75.6M end of 2025; raised $112.7M financing net proceeds during the year.

Lead Asset Positive PET Data Reported positive top-line Phase 1b PET data for PIPE-791 in September 2025; Phase 2 IPF trial initiated December 2025.

Increased R&D Investment Total R&D expenses rose to $51.5M in 2025, driven by increased CRO costs for ongoing clinical trials.

PIPE-307 Phase 2 Data Reported Phase 2 VISTA trial for PIPE-307 (RRMS) showed acceptable safety but missed primary efficacy endpoints in November 2025.

リスク要因

Heavy Drug Candidate Dependency Business materially harmed if lead candidates PIPE-791 or PIPE-307 fail clinical development or regulatory approval processes.

Sustained Operating Expense Increases Incurred $68.1M total operating expenses in 2025; anticipates continued increases, risking inability to sustain profitability.

Regulatory Approval Unpredictability Research, testing, and approval processes are subject to extensive, lengthy, and unpredictable regulation by FDA and foreign authorities.

J&J Discretion Over PIPE-307 Future development of PIPE-307 relies solely on J&J's discretion following completion of Phase 2 RRMS trial data.

見通し

Anticipated Chronic Pain Data Expect top-line data from exploratory Phase 1b chronic pain trial (COAP/CLBP) for PIPE-791 in the second quarter of 2026.

Continued J&J Phase 2 Development J&J recruiting for Phase 2 MDD trial (Moonlight-1) for PIPE-307; development for RRMS remains at J&J's discretion.

Future Capital Requirements Expected Expect significant future funding needs for clinical trials, regulatory submissions, and expanding internal commercialization capabilities.

Focus on Core Pipeline Advancement Strategy centers on balanced development minimizing clinical risk for PIPE-791 (IPF/Pain) and partnered PIPE-307 (MDD/RRMS).

同業比較

売上高 (TTM)

VNDA

$216.11M

+8.7%

AMRN

$183.87M

-19.6%

EDIT

$40.52M

+25.4%

粗利益率 (最新四半期)

AMRN

119.2%

+7.3pp

ACIU

100.0%

+0.0pp

EDIT

96.7%

+2621.3pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CAPR	$1.53B	-18.6	-71.0%	11.5%
ANNX	$650.60M	-3.9	-92.3%	11.8%
VNDA	$549.11M	-2.5	-49.2%	2.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月13日

EPS:-$0.53

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし